These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 25417413)

  • 1. Establishment of safety evidence for Xingxue Shuxuening injection.
    Yang W; Zhang W; Xie Y; Han B
    J Tradit Chin Med; 2014 Oct; 34(5):604-8. PubMed ID: 25417413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Intensive hospital monitoring of Shuxuening injection in 30 209 cases].
    Jiang JJ; Xie YM; Zhang Y; Li MQ; Zhao YB; Wen ZH; Li XL; Yi DH; Zhang YK
    Zhongguo Zhong Yao Za Zhi; 2017 Aug; 42(15):2883-2888. PubMed ID: 29139252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reevaluation of the post-marketing safety of Shuxuening injection based on real-world and evidence-based evaluations.
    Wang C; Shi QP; Ding F; Jiang XD; Tang W; Yu ML; Zhu JH
    Drug Des Devel Ther; 2018; 12():757-767. PubMed ID: 29670332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postmarketing safety evaluation: depside salt injection made from Danshen (Radix Salviae Miltiorrhizae).
    Chang Y; Zhang W; Xie Y; Xu X; Sun R; Wang Z; Yan R
    J Tradit Chin Med; 2014 Dec; 34(6):749-53. PubMed ID: 25618981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postmarketing studies on safety of Dengfeng shenmai injection.
    Wang L; Zhang W; Xie Y; Bai Y; Wang M; Ai Q
    J Tradit Chin Med; 2013 Dec; 33(6):827-31. PubMed ID: 24660618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Study of post marketing safety reevaluation of shenqi fuzheng injection].
    Ai QH; Li YY; Xie YM
    Zhongguo Zhong Yao Za Zhi; 2014 Sep; 39(18):3633-6. PubMed ID: 25532410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of adverse reactions and pharmacovigilance research to parenterally administered shuxuening].
    Yang W; Xiang YY; Xie YM; Shen H
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):3013-8. PubMed ID: 24471322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reevaluation of the post-marketing safety of Xuebijing injection based on real-world and evidence-based evaluations.
    Wang C; Shi QP; Ding F; Jiang XD; Tang W; Yu ML; Cheng JQ
    Biomed Pharmacother; 2019 Jan; 109():1523-1531. PubMed ID: 30551404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-marketing safety monitoring of shenqifuzheng injection: a solution made of dangshen (Radix Codonopsis) and huangqi (Radix Astragali Mongolici).
    Ai Q; Zhang W; Xie Y; Huang W; Liang H; Cao H
    J Tradit Chin Med; 2014 Aug; 34(4):498-503. PubMed ID: 25185371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Apply association rules to analysis adverse drug reactions of shuxuening injection based on spontaneous reporting system data].
    Yang W; Xie YM; Xiang YY
    Zhongguo Zhong Yao Za Zhi; 2014 Sep; 39(18):3616-20. PubMed ID: 25532406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of the Xuesaitong injection in China: results from a large-scale multicentre post-marketing surveillance study in a real-world setting.
    He Y; Gao XM; Li L; Liu XG; Liu W; Hong XJ; Huang BH; Yang HL; Xue MH; Wu XJ; Liu JF
    Curr Med Res Opin; 2020 Dec; 36(12):1947-1953. PubMed ID: 33016133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Technical specifications for intensive hospital safety monitoring of post-marketing Chinese medicine (draft version for comments)].
    Xie YM; Liao X; Zhao YB; Li MQ; Zhang YL; Ma R; Xian SX; Liu J; Li SY; Wen ZH; Yang ZQ; Zou JD; Sun HS; He Y; Li XL; Jiang JJ; Wang ZF; Li YY; Wang LX; Chang YP; Yang W; Zhang W
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2919-24. PubMed ID: 24471304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-marketing safety surveillance and re-evaluation of Xueshuantong injection.
    Li C; Xu T; Zhou P; Zhang J; Guan G; Zhang H; Ling X; Li W; Meng F; Liu G; Lv L; Yuan J; Li X; Zhu M
    BMC Complement Altern Med; 2018 Oct; 18(1):277. PubMed ID: 30326892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Post-marketing safety surveillance of Diemailing Kudiezi injection: real world study in 30 233 cases].
    Liao X; Yu DD; Xie YM; Zhang YL; He Y; Zhang Y; Liu Y; Yi DH; Wang YY
    Zhongguo Zhong Yao Za Zhi; 2017 Aug; 42(15):2857-2863. PubMed ID: 29139248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Post-marketing clinical safety assessment of Shenmai injection based on active monitoring and passive monitoring in large data background].
    Wang LX; Xie YM; Ai QH; Song NB
    Zhongguo Zhong Yao Za Zhi; 2015 Dec; 40(24):4752-6. PubMed ID: 27245017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical safety studies based on 30 026 post-marketing cases of Shenqi Fuzheng injection by intensive hospital monitoring nested NCCS].
    Wang LX; Xie YM; Ai QH; Xu WF
    Zhongguo Zhong Yao Za Zhi; 2015 Dec; 40(24):4739-45. PubMed ID: 27245015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect and safety of Shengxuening (extract from excrement of bombyxin) for renal anemia: a systematic review.
    Zhang L; Zhang W; Jin H; Wang D; Wei N; Wang Y
    J Tradit Chin Med; 2016 Oct; 36(5):588-95. PubMed ID: 29932629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Analysis of clinical use of post-marketing hospital centralized monitoring of Xiyanping injection].
    Zhao Y; Shi C; Huang P
    Zhongguo Zhong Yao Za Zhi; 2016 Feb; 41(4):743-747. PubMed ID: 28871704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Building safety evidence body of shuxuetong injection].
    Jiang JJ; Liao X; Xie YM
    Zhongguo Zhong Yao Za Zhi; 2014 Sep; 39(18):3630-2. PubMed ID: 25532409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical comprehensive evaluation of Ginkgolide Injection in treatment of cerebral infarction].
    Liu FM; Xie YM; Wang ZF; Zhang Q; Cui X
    Zhongguo Zhong Yao Za Zhi; 2022 Mar; 47(6):1493-1500. PubMed ID: 35347948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.